Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Jenks, JD; Salzer, HJ; Prattes, J; Krause, R; Buchheidt, D; Hoenigl, M.
Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.
Drug Des Devel Ther. 2018; 12(3):1033-1044
Doi: 10.2147/DDDT.S145545
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Hönigl Martin
- Co-Autor*innen der Med Uni Graz
- Krause Robert
- Prattes Jürgen
- Salzer Helmut J. F.
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- In recent decades, important advances have been made in the diagnosis and treatment of invasive aspergillosis (IA) and mucormycosis. One of these advances has been the introduction of isavuconazole, a second-generation broad spectrum triazole with a favorable pharmacokinetic and safety profile and few drug-drug interactions. Phase III trials in patients with IA and mucormycosis demonstrated that isavuconazole has similar efficacy to voriconazole for the treatment of IA (SECURE trial) and liposomal amphotericin B for the treatment of mucormycosis (VITAL trial with subsequent case-control analysis) and a favorable safety profile with significantly fewer ocular, hepatobiliary, and skin and soft tissue adverse events compared to voriconazole. As a result, recent IA guidelines recommend isavuconazole (together with voriconazole) as gold standard treatment for IA in patients with underlying hematological malignancies. In contrast to liposomal amphotericin B, isavuconazole can be safely administered in patients with reduced renal function and is frequently used for the treatment of mucormycosis in patients with reduced renal function. Updated guidelines on mucormycosis are needed to reflect the current evidence and give guidance on the use of isavuconazole for mucormycosis. Studies are needed to evaluate the role of isavuconazole for 1) anti-mold prophylaxis in high-risk patients, 2) salvage treatment for IA and mucormycosis, and 3) treatment for other mold infections such as Scedosporium apiospermum.
- Find related publications in this database (using NLM MeSH Indexing)
- Animals -
- Antifungal Agents - chemistry
- Antifungal Agents - metabolism
- Antifungal Agents - therapeutic use
- Aspergillosis - drug therapy
- Drug Design -
- Humans -
- Mucormycosis - drug therapy
- Nitriles - chemistry
- Nitriles - metabolism
- Nitriles - therapeutic use
- Pyridines - chemistry
- Pyridines - metabolism
- Pyridines - therapeutic use
- Triazoles - chemistry
- Triazoles - metabolism
- Triazoles - therapeutic use
- Find related publications in this database (Keywords)
- TDM
- plasma level
- triazole
- SECURE
- VITAL
- susceptibility
- real life